SCHEMBL8580567

SCHEMBL8580567

CS(=O)(=O)OC(CCl)c1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP24A1 Q07973 1/20 0.35
ALDH1A1 P00352 2/20 0.35
CYP3A4 P08684 1/20 0.35
GSR P00390 1/20 0.35
CYP2C19 P33261 1/20 0.34
SLC6A4 P31645 2/20 0.34
SLC6A9 P48067 1/20 0.33
KMT2A Q03164 2/20 0.33
NPC1 O15118 1/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
HTT P42858 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CHRNB2 P17787 1/20 0.33
CHRNA4 P43681 1/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA7 P43166 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10799609 0.90 GRIA4 (0.41) ALDH1A1NPC1HTTRAB9ASMN1; SMN2
SCHEMBL2073576 0.86 CYP24A1 (0.37) CYP24A1ALDH1A1CYP3A4GSRCYP2C19
SCHEMBL12933943 0.86 CYP24A1 (0.37) CYP24A1ALDH1A1CYP3A4GSRCYP2C19
SCHEMBL10804854 0.85 ALDH1A1 (0.32) ALDH1A1
SCHEMBL17831448 0.84 AOC3 (0.40) ALDH1A1CYP3A4SLC6A4LMNASMN1; SMN2
SCHEMBL10800321 0.84 ALDH1A1 (0.35) ALDH1A1CYP3A4CYP2C19KMT2ALMNA
SCHEMBL8126233 0.83 LMNA (0.41) CYP24A1ALDH1A1CYP3A4GSRCYP2C19
SCHEMBL10800000 0.82 HPGD (0.38) CYP24A1ALDH1A1NPC1LMNAHTT
SCHEMBL17831449 0.82 AOC3 (0.46) ALDH1A1SLC6A4KMT2A
SCHEMBL27850787 0.81 ALDH1A1 (0.39) CYP24A1ALDH1A1CYP3A4GSRCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10703744-B2 Process for preparation of luliconazole GLENMARK LIFE SCIENCES LIMITED (IN) 2020-07-07 US disclosed
US-20170362212-A1 PROCESS FOR PREPARATION OF LULICONAZOLE GLENMARK LIFE SCIENCES LIMITED (IN) 2017-12-21 US disclosed
US-20170362212-A1 PROCESS FOR PREPARATION OF LULICONAZOLE GLENMARK LIFE SCIENCES LIMITED (IN) 2017-12-21 US disclosed
WO-2016092478-A1 PROCESS FOR PREPARATION OF LULICONAZOLE GLENMARK PHARMACEUTICALS LIMITED (IN) 2016-06-16 WO disclosed
WO-1998011895-A1 A METHOD FOR THE PREVENTION OF MIGRAINE ELI LILLY AND COMPANY (US) 1998-03-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170362212-A1 PROCESS FOR PREPARATION OF LULICONAZOLE LSS, CYP51A1, THPO CYP24A1 1621/4885ALDH1A1 2310/4885CYP3A4 15/4885
US-10703744-B2 Process for preparation of luliconazole LSS, CYP51A1, THPO CYP24A1 1621/4885ALDH1A1 2310/4885CYP3A4 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.